An antigen-encapsulating nanoparticle platform for T_H1/17 immune tolerance therapy

Area of Science:

• Immunology
• Nanomedicine
• Autoimmune Disease Therapy

Background:

• Tolerogenic nanoparticles (NPs) are promising immunotherapies for autoimmune diseases.
• Current NP therapies face challenges like antibody binding and the need for co-administered immunosuppressants.

Purpose of the Study:

• To develop antigen-encapsulated NPs (PLG(Ag)) for inducing antigen-specific tolerance.
• To investigate the mechanism of action of PLG(Ag) in a model of autoimmune T helper type 1/17 dysfunction.

Main Methods:

• Developed poly(lactide-co-glycolide) nanoparticles encapsulating antigen (PLG(Ag)).
• Utilized a relapse-remitting experimental autoimmune encephalomyelitis (R-EAE) model to assess disease abrogation.
• Investigated NP biodistribution, cellular interactions, and immune checkpoint molecule expression (PD-L1/PD-1).

Main Results:

• PLG(Ag) completely abrogated R-EAE induction in an organ-specific manner, with the spleen being dispensable.
• Intravenously administered PLG(Ag) localized to the liver, interacting with macrophages and recruiting antigen-specific T cells.
• Upregulation of programmed death ligand 1 (PD-L1) on antigen-presenting cells was observed, and PD-1 blockade reduced tolerance induction.

Conclusions:

• PLG(Ag) NPs effectively induce antigen-specific tolerance without requiring co-delivered immunosuppressive drugs.
• The findings suggest that PLG(Ag) NPs leverage endogenous tolerogenic pathways for immunotherapy.
• This approach offers a safer and potentially more effective strategy for treating autoimmune diseases.